Companies · Biotechnology

ShouTi Inc.

SOUTH SAN FRANCISCO · Biotechnology

Diligence memoA one-page analyst read on ShouTi Inc. — recommendation, valuation, rhythm, risks.
$165.0M
Total raised · real
4
Rounds
0.1×
Latest step-up
Top 6%
Sector rank · raised
Series D+
Latest stage · inferred · Wed Dec 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

ShouTi Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

ShouTi Inc. is one of 4291 Biotechnology companies tracked from SOUTH SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 95% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2019
Year incorporated
2021-12-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2019-04-29 Raised $32M (real) Modeled valuation $1.3B (est)$32M$1.3BSeries B2019Series B · 2020-03-11 Raised $26M (real) Modeled valuation $1.0B (est)$26M$1.0BSeries B2020Series D+ · 2021-07-30 Raised $100M (real) Modeled valuation $2.9B (est)$100M$2.9BSeries D+2021Series D+ · 2021-12-15 Raised $7.0M (real) Modeled valuation $178M (est)$7.0M$178MSeries D+2021+$26M+$100M+$7.0MCumulative $165M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$32.0M · 2019
Series B extension$26.0M · 2020
Series D+$100.0M · 2021no Series C on file
Series D+ extension$7.0M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$178.2M
Base estimate est.
$31.7M
Conservative case
$330.6M
Upside case
$58.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.3B · 2019-04-292019Series B · modeled $1.0B · 2020-03-11Series D+ · modeled $2.9B · 2021-07-30Series D+ · modeled $178.2M · 2021-12-152021
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
4.5 yr
Elapsed time used
4.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$62.7M/yr
Capital velocity
7.2 yr
On record since
2019
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 23× above median
This company$165.0M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.1× of median
This company$7.0M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 2.8× above median
This company$178.2M
Sector median$64.2M

Raised more than 95% of sector peers (real $). Modeled value above 70% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #58 of 58.

This companyCohort peer
$100.0M$1.0B$10.0B$100.0B$100.0M$1.0BCapital raised (log)Sarepta Therapeutics, Inc. · Series D+ Raised $430.5M · modeled $16.5B (est)Asklepios BioPharmaceutical, Inc. · Series D+ Raised $199.7M · modeled $8.2B (est)Affinivax, Inc. · Series D+ Raised $233.0M · modeled $7.8B (est)Sonoma Biotherapeutics, Inc. · Series D+ Raised $265.0M · modeled $7.7B (est)Instil Bio, Inc. · Series D+ Raised $381.2M · modeled $6.5B (est)Umoja Biopharma, Inc. · Series D+ Raised $210.0M · modeled $6.3B (est)NiKang Therapeutics, Inc. · Series D+ Raised $200.0M · modeled $6.2B (est)Insitro, Inc. · Series D+ Raised $143.2M · modeled $5.9B (est)Arbor Biotechnologies, Inc. · Series D+ Raised $230.6M · modeled $5.7B (est)VelosBio Inc. · Series D+ Raised $210.5M · modeled $5.6B (est)Erasca, Inc. · Series D+ Raised $183.7M · modeled $5.2B (est)Allovir, Inc. · Series D+ Raised $151.3M · modeled $5.0B (est)ShouTi Inc. (this company) Raised $165.0M · modeled $178.2M (est)ShouTi Inc.
CompanyStageRaised · realValue · estvs peer med.
Sarepta Therapeutics, Inc.Series D+$430.5M$16.5B3.92×
Asklepios BioPharmaceutical, Inc.Series D+$199.7M$8.2B1.96×
Affinivax, Inc.Series D+$233.0M$7.8B1.86×
Sonoma Biotherapeutics, Inc.Series D+$265.0M$7.7B1.82×
Instil Bio, Inc.Series D+$381.2M$6.5B1.54×
Umoja Biopharma, Inc.Series D+$210.0M$6.3B1.51×
NiKang Therapeutics, Inc.Series D+$200.0M$6.2B1.46×
Insitro, Inc.Series D+$143.2M$5.9B1.40×
Arbor Biotechnologies, Inc.Series D+$230.6M$5.7B1.36×
VelosBio Inc.Series D+$210.5M$5.6B1.33×
Erasca, Inc.Series D+$183.7M$5.2B1.23×
Allovir, Inc.Series D+$151.3M$5.0B1.19×
ShouTi Inc. this companySeries D+$165.0M$178.2M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$32.0M2019-04-29$177.8M$1.3B90%
Series B$26.0M2020-03-11$144.4M$1.0B90%
Series D+$100.0M2021-07-30$833.3M$2.9B90%
Series D+$7.0M2021-12-15$58.3M$178.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$32.0M2019-04-29
    • First recorded raise — entered as Series B.
    • 6 investors on this round.
  2. Series B$26.0M2020-03-11
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 9 investors on this round.
  3. Series D+$100.0M2021-07-30
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 30 investors on this round.
  4. Series D+$7.0M2021-12-15
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 14.3× smaller than the prior — bridge or down round.
    • 8 investors on this round.
Intelligence
2022 ~Q4
Modeled next raise · ~11mo cadence
$7.0M
Modeled next size est.range $7.0M$11.2M
0.1×
Last step-up
$62.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Weisskoff11 other2019-04
Ramy Farid4 other2019-04
Daniel Auerbach2 other2019-04
Raymond Stevens2 other2019-04
Chen-Ming Yu1 other2019-04
Cuiping Gu2019-04
Jessica Lifton2019-04
Jun Yoon2019-04
Ting Xie2019-04
Registry & provenance

ShouTi Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1888886
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Schrodinger, Inc.BiotechnologySeries D+$159.8M$4.4Bnetwork1 shared operator · same sector · same stage
Caribou Biosciences, Inc.BiotechnologySeries D+$141.0M$3.8Bnetwork1 shared operator · same sector · same stage
Semma Therapeutics, Inc.BiotechnologySeries D+$129.3M$4.7Bnetwork1 shared operator · same sector · same stage
Basecamp Bio Inc.BiotechnologySeries A$9.0M$229.4Mnetwork2 shared operators · same sector
Checkmate Pharmaceuticals, Inc.BiotechnologySeries C$185.1M$3.5Bnetwork1 shared operator · same sector
Xilio Therapeutics, Inc.BiotechnologySeries C$145.2M$3.0Bnetwork1 shared operator · same sector
Ajax Therapeutics, Inc.BiotechnologySeries C$140.4M$907.0Mnetwork1 shared operator · same sector
Morphic Holding, Inc.BiotechnologySeries C$200.6M$1.5Bnetwork1 shared operator · same sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Pearl Bio, Inc.BiotechnologySeries A$84.6M84%
Sound Pharmaceuticals IncBiotechnologySeries A$304.0M84%
OraLiva, Inc.BiotechnologySeed$5.1M83%
BluDiagnostics, Inc.BiotechnologySeed$151.0M83%
Oral Genome Corp.BiotechnologySeed$11.2M83%
AGI Scientific, LLCBiotechnologySeries A$100.2M82%
MuscleSound, Inc.BiotechnologySeed$962K82%
Genesis New Ventures, LLCBiotechnologyPre-Seed$1.7M82%
Frequently asked
How much funding has ShouTi Inc. raised?
ShouTi Inc. has raised approximately $165.0M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is ShouTi Inc.'s estimated valuation?
Provath's modeled valuation for ShouTi Inc. is approximately $178.2M (modeled range $31.7M–$330.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ShouTi Inc. at?
ShouTi Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Wed Dec 15.
What does ShouTi Inc. do and where is it based?
ShouTi Inc. operates in the Biotechnology sector, based in SOUTH SAN FRANCISCO.
Explore related

See where ShouTi Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ShouTi Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.